Prospective evaluation of CAR-T cell therapy-related proteinuria and kidney dysfunction
Open Access
- 27 August 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (10) , sfaf270
Abstract
Background: The nephrotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy has been reported, yet data on urinary abnormalities remain limited. This study aimed to characterize proteinuria, acute kidney injury (AKI), and associated electrolyte disorders in patients treated with CAR-T therapy. Methods: A prospective analysis was conducted on 63 patients treated with CAR-T therapy between June 2020 and December 2023. Blood tests were collected daily during hospitalization and a first morning urine void was collected on day of infusion (D0), +7 (D7), and +14 (D14). Results: During the study period, 12 patients (19%) developed AKI. The median urine protein-to-creatinine ratio (uPCR) increased significantly from 0.17 g/g on D0 to 0.39 g/g on D7, returning to baseline levels at D14. Proteinuria >0.5 g/g was detected in 37% of patients at D7. Patients with AKI before D7 had higher proteinuria than patients without AKI or AKI after D7. Proteinuria was associated with higher levels of lactate dehydrogenase (LDH), interleukin-6 levels and cytokine release syndrome (CRS) grade $\ge$3. Patients with higher proteinuria had more progression of hematological disease and increased mortality in the first year. Furthermore, 60 patients (95%) experienced at least one electrolyte disorder, hypophosphatemia being the most frequent. Higher proteinuria was associated with lower levels of phosphorus, potassium, and sodium. Conclusions: CAR-T therapy is associated with transient renal adverse effects, including proteinuria, AKI, and electrolyte disorders. Systemic inflammation-mediated tubular injury contributed to these adverse effects. These findings enhance our understanding of CAR-T therapy nephrotoxicity. Proteinuria levels at D0 may be associated with disease progression and mortality within the first year.Keywords
Funding Information
- Fundación Senefro
- Sociedad Española de Nefrología
- Instituto de Salud Carlos III RICORS program (RICORS2040, RD21/0005/0022)
- European Union—NextGenerationEU
This publication has 22 references indexed in Scilit:
- The complex interplay between kidney injury and inflammationClinical Kidney Journal, 2020
- Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid RecoveryTransplantation and Cellular Therapy, 2020
- Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell LymphomaAmerican Journal of Kidney Diseases, 2020
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Engineering CAR-T cellsBiomarker Research, 2017
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Work Group MembershipKidney International Supplements, 2012
- NGAL in Acute Kidney Injury: From Serendipity to UtilityAmerican Journal of Kidney Diseases, 2008
- Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injuryAmerican Journal of Physiology-Renal Physiology, 2006
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993